Facebook Twitter LinkedIn YouTube Instagram

To navigate the following site navigation expect to utilize the tab key to move through items sequentially. The spacebar or enter keys can be utilized to interact with items that open sub-navigation.

The next tab will be the search box toggle. Hit enter to open the search, focus will automatically shift to the search bar. Type a letter into the search input and suggested results will appear.

Drug

Leramistat

Status:

Phase 2

Condition:

Idiopathic Pulmonary Fibrosis

Intervention Type:

Oral Drug

Funder Type:

Industry

Drug Details

Leramistat is a first-in-class programmed disease-resolving drug.

Study Purpose

This will be a Phase 2, double-blind, placebo-controlled, 2-arm, parallel-group, multicenter study to investigate leramistat treatment of patients aged 40 years or older with idiopathic pulmonary fibrosis (IPF).

Find a Clinical Trial